KIT
KIT
REPORT
Readings from a Dexcom CGM (left) feeds into the
CamAPS FX app as seen on the smartphone screens
above. It then manages both basal and bolus insulin
delivery via the Dana RS insulin pump, making it a closed
loop system - an 'artifical pancreas'..
this country, as the system works at the
moment, each CCG has a slightly different
approach to funding and it is often on
a case by case basisWe are making
progress in many areas like Southampton,
Nottingham, Manchester, and London
to name a few. It is challenging but
approaching funding teams one by one is
currently the only way. Decisions are made
locally about the adoption of technology."
At this point in the webinar, JDRF's
says Rachel Connor adds, "JDRF is
pushing for national decisions to be made
on new products which should make life
easier for people with Type 1 diabetes until
we get a cure. Usually with good research,
clinicians are quickly persuaded. It's a little
harder with commissioners, as they may
not know Type 1 diabetes in detail. But
research data is not enough, we have to
campaign too. People with diabetes need
to ask their diabetes teams about the
tech; they probably won't come to you
about it, so go to them."
JDRF has an initiative called Pathways
to Choice, the purpose of which is to
make it as smooth as possible to get a
choice regarding diabetes technology, no
matter where they live. Connor says, "We
are keen for people to feel that they have,
and actually have a choice. The idea is
for an 'open protocol' system, where
you can pick and choose elements that
work best for you. We're all different and
have different preferences, so you need to
work with what's best for you. We're not
there yet but we're getting there."
continued over